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Background
Cardiac metastases (CMET) impact management and
clinical outcomes of patients with systemic neoplasms.
CMR is well validated for evaluation of cardiac masses
and increasingly used to assess oncologic patients,
among whom pattern, tissue characteristics, and optimal
diagnostic strategies for CMET are not known.
Methods
The population comprised consecutive adults (≥18 yo)
with metastatic systemic neoplasms who underwent
contrast-enhanced CMR between 1/2012 - 8/2015.
Patients with primary cardiac neoplasms were excluded.
CMR was performed using 1.5T (88%) and 3T (12%)
clinical (GE) scanners. A standard contrast-enhanced
CMR protocol was applied: Cine-CMR (SSFP) was used
to assess cardiac structure and morphology. DE-CMR
(IR-GRE, TI 250-350 msec, 0.2 mmol/kg gadolinium)
was used for tissue characterization; long TI (600 msec)
DE-CMR was employed to confirm tissue properties of
visualized masses. CMET was defined using established
criteria as a discrete, irregularly contoured mass with
discrete borders independent of cardiac chambers, myo-
cardium, or central catheters. CMET was further cate-
gorized based on enhancement pattern (absent, diffuse,
heterogeneous enhancement with patchy hypoenhance-
ment). Transthoracic echocardiography (echo), if per-
formed clinically within 30 days of CMR, was used to
test conventional imaging for CMET.
Results
115 patients (57 ± 15 yo, 54% male) with metastatic
extra-cardiac primary neoplasms were studied; 29%
(n=33) had CMET on CMR. Sarcoma (21% [n=7]) and
melanoma (12% [n=4]) were the two leading primary
cancer etiologies; atypical primaries also occurred (n=3
pancreatic, n=1 gastrointestinal stromal, n=1 CNS).
CMET location markedly varied (45% RV | 27% LV |
18% RA | 12% LA | 27% pericardial); 21% of cases
involved multiple cardiac locations. 76% were due to
hematogenous or lymphatic spread; 24% were due to
direct invasion. DE-CMR demonstrated CMET enhance-
ment in 83% of cases; enhancement pattern was variable
(54% heterogeneous, 46% diffuse). CMET often occurred
in absence of pericardial (27%) or pleural (48%) effu-
sions. 67% of the population underwent echo within 30
(6.7 ± 8.0) days of CMR, including 61% (n=20) of
patients with CMET by CMR. As shown (Table 1), echo
provided limited diagnostic sensitivity for CMET,
whether assessed on a per-patient (75%) or per-location
(74%) basis, despite excellent specificity (≥98%). Echo
performance varied based on CMET morphology and
location; CMET detected by CMR but missed by echo
were either intra-myocardial (n=2) or in locations sub-
optimally evaluated via transthoracic ultrasound (n=2
posterior LA | n=1 RV outflow tract).
Conclusions
CMET vary in location and enhancement pattern on
CMR, often presenting without typical adjunctive find-
ings such as pericardial or pleural effusions. Conven-
tional screening via echo can be limited for CMET
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detection; incremental utility of CMR is typically pro-
vided for neoplasms that are intramyocardial or atypical
in location.
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Table 1 Diagnostic Performance of Transthoracic Echo for CMET as Established by CMR
Sensitivity Specificity Accuracy Positive Predictive Value Negative Predictive Value
Echo (per-patient) 75% (15/20) 98% (55/56) 92% (71/77) 94% (15/16) 91% (56/61)
Echo (location-specific) 74% (17/23) 99% (354/357) 98% (371/380) 85% (17/20) 98% (354/360)
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